Carlsmed's aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures

Core Insights - Carlsmed, Inc. has received NTAP reimbursement approval from CMS for its aprevo® personalized interbody implants used in cervical fusion procedures, effective October 1, 2025, which will provide up to an additional $21,125 in reimbursement for qualifying inpatient procedures [1][2][3] Company Overview - Carlsmed is a medical technology company focused on AI-enabled personalized spine surgery solutions, aiming to improve patient outcomes and reduce healthcare costs [4] Technology and Innovation - The aprevo® devices are designed to cater to the unique anatomical and alignment needs of each patient through an AI-powered surgical planning platform and digital production system [3] - The company has received Breakthrough Device designation from the FDA for cervical use and plans to launch the product commercially in the U.S. in 2026 [3]